Overview of key molecular and pharmacological targets for diabetes and associated diseases

LIFE SCIENCES

卷:278

Article

Shahcheraghi, Seyed Hossein^1,2  Aljabali, Alaa A. A.³  Al Zoubi, Mazhar S.⁴  Mishra, Vijay⁵  Charbe, Nitin B.⁶  Haggag, Yusuf A.⁷  Shrivastava, Garima⁸  Almutary, Abdulmajeed G.⁹  Alnuqaydan, Abdullah M.⁹  Barh, Debmalya¹⁰  Dua, Kamal¹¹  Chellappan, Dinesh K.¹²  Gupta, Gaurav¹³  Lotfi, Marzieh¹⁴  Serrano-Aroca, Angel¹⁵  Bahar, Bojlul¹⁶  Mishra, Yogendra Kumar¹⁷  Takayama, Kazuo¹⁸  Panda, Pritam Kumar¹⁹  Bakshi, Hamid A.²⁰  Tambuwala, Murtaza M.²⁰ 

[1] Shahid Sadoughi Univ Med Sci, Shahid Sadoughi Hosp, Infect Dis Res Ctr, Yazd, Iran

[2] Shahid Sadoughi Univ Med Sci, Sch Med, Dept Med Genet, Yazd, Iran

[3] Yarmouk Univ, Dept Pharmaceut & Pharmaceut Technol, Irbid, Jordan

[4] Yarmouk Univ, Fac Med, Dept Basic Med Sci, Irbid, Jordan

[5] Lovely Profess Univ, Sch Pharmaceut Sci, Phagwara 144411, Punjab, India

[6] Texas A&M Hlth Sci Ctr, Irma Lerma Rangel Coll Pharm, Dept Pharmaceut Sci, Kingsville, TX 78363 USA

[7] Tanta Univ, Fac Pharm, Dept Pharmaceut Technol, Tanta, Egypt

[8] Indian Inst Technol, Delhi, India

[9] Qassim Univ, Coll Appl Med Sci, Dept Med Biotechnol, Buraydah, Saudi Arabia

[10] Inst Integrat Omics & Appl, Ctr Genom & Appl Gene Technol, Purba Medinipur, W Bengal, India

[11] Univ Technol Sydney, Grad Sch Hlth, Discipline Pharm, Ultimo, NSW 2007, Australia

[12] Int Med Univ, Sch Pharm, Dept Life Sci, Kuala Lumpur, Malaysia

[13] Suresh Gyan Vihar Univ, Sch Pharm, Mahal Rd, Jaipur, Rajasthan, India

[14] Shahid Sadoughi Univ Med Sci, Abort Res Ctr, Reprod Sci Inst, Yazd, Iran

[15] Catholic Univ Valencia San Vicente M Rtir, Translat Res Ctr San Alberto Magno, Biomat & Bioengn Lab, C Guillem de Castro 94, Valencia 46001, Spain

[16] Univ Cent Lancashire, Res Ctr Global Dev, Sch Sport & Hlth Sci, Nutr Sci & Appl Food Safety Studies, Preston PR1 2HE, Lancs, England

[17] Univ Southern Denmark, Mads Clausen Inst, NanoSYD, Alsion 2, DK-6400 Sonderborg, Denmark

[18] Kyoto Univ, Ctr IPS Cell Res & Applicat, Kyoto 6068397, Japan

[19] Uppsala Univ, Dept Phys & Astron, Mat Theory Div, Condensed Matter Theory Grp, Box 516, S-75120 Uppsala, Sweden

[20] Ulster Univ, Sch Pharm & Pharmaceut Sci, Coleraine BT52 1SA, Londonderry, North Ireland

关键词: Diabetes;    Diabetic complications;    Signaling pathways;    Molecular pharmacology;    Targets;   

DOI  :  10.1016/j.lfs.2021.119632

来源: Elsevier

【 摘 要 】

of diabetes. This review assesses the newest researches about the key molecules and signaling pathways as targets of molecular pharmacology in diabetes and diseases related to it for better treatment based on molecular sciences. The disease is not cured by current pharmacological strategies for type 2 diabetes. While several drug combinations are accessible that can efficiently modulate glycemia and mitigate long-term complications, these agents do not reverse pathogenesis, and in practice, they are not established to modify the patient's specific molecular profiling. Therapeutic companies have benefited from human genetics. Genome exploration, which is agnostic to the information that exists, has revealed tens of loci that impact glycemic modulation. The physiological report has begun to examine subtypes of diseases, illustrate heterogeneity and propose biochemical Diabetes epidemiological quantities are demonstrating one of the most important communities' health worries. The essential diabetic difficulties are including cardiomyopathy, nephropathy, inflammation, and retinopathy. Despite developments in glucose decreasing treatments and drugs, these diabetic complications are still inef-fectively reversed or prohibited. Several signaling and molecular pathways are vital targets in the new therapies of diabetes. This review assesses the newest researches about the key molecules and signaling pathways as targets of molecular pharmacology in diabetes and diseases related to it for better treatment based on molecular sciences. The disease is not cured by current pharmacological strategies for type 2 diabetes. While several drug combinations are accessible that can efficiently modulate glycemia and mitigate long-term complications, these agents do not reverse pathogenesis, and in practice, they are not established to modify the patient's specific molecular profiling. Therapeutic companies have benefited from human genetics. Genome exploration, which is agnostic to the information that exists, has revealed tens of loci that impact glycemic modulation. The physiological report has begun to examine subtypes of diseases, illustrate heterogeneity and propose biochemical therapeutic pathways.

【 授权许可】

Free